Skip to main content Skip to section navigation Skip to footer
Rezolute, Inc. IR Overview
  • About
    • Our Mission
    • Leadership
    • Board of Directors
  • Our Science
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • Patient Stories
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us

News

Investors

Investors

  • Overview
  • Corporate Presentation
  • Patient Stories
  • News
  • Events
  • Stock Quote and Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Info
Jun 8, 2015 7:30 am EDT
AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
May 11, 2015 8:00 am EDT
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
Jan 8, 2015 7:35 am EST
AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
Jan 7, 2015 8:00 am EST
AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
Jan 5, 2015 7:35 am EST
AntriaBio Announces $7 Million Private Placement
Nov 10, 2014 8:05 am EST
AntriaBio Extinguishes $44 Million Contingent Liability
Jul 23, 2014 7:35 am EDT
AntriaBio Appoints Barry Sherman, M.D. to Its Board of Directors
Jun 23, 2014 7:35 am EDT
AntriaBio Appoints C. Ronald Kahn, M.D. to Its Scientific Advisory Board
May 22, 2014 7:35 am EDT
AntriaBio, Inc. to Present at the Third Annual Marcum MicroCap Conference on Thursday, May 29, 2014
May 12, 2014 7:35 am EDT
AntriaBio, Inc. Establishes Manufacturing and Laboratory Facility in Colorado
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Next Pagearrow_forward
rss_feed News RSS

Stay Connected

  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Visit us on LinkedIn Visit us on X Visit us on Facebook
rezolute logo

©2025 Rezolute, Inc.

Explore

  • About
  • Approach
  • Pipeline
  • Publications
  • For Patients
  • Join Us
  • Investors & Media
  • Contact Us

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065

+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Oregon Office
2783 NW Lolo Drive
Suite 150
Bend, OR 97703

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Approach
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • Patient Stories
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us